IRLAB Therapeutics AB (IRLAB-A) Fair Value & Analysis
Healthcare · SE · Market cap 121M SEK (≈ $12.7M) · ISIN SE0012675361
What is IRLAB Therapeutics AB really worth?
Below-average quality, and trading another 287% above our fair value of kr 0.4420.
As of Aug 22, 2026, the fair value of IRLAB Therapeutics AB is kr 0.4420 per share against a price of kr 1.71, so the fair value sits 74% below the price. A model estimate blended from multiple valuation models, recalculated regularly.
Risks
Fair value as of: Aug 22, 2026
From 3 valuation models · updated 14 days ago
Share price +25.9% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (kr 0.6120). The favourable scenario is already priced in.
- Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (kr 0.2465 to kr 0.6120) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.
How to read this chart
60‑month range kr 1.20 – kr 70.00 · fair‑value band kr 0.2465 – kr 0.6120 · the kr 1.71 price screens above the kr 0.4420 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 22, 2026.
Analysis
IRLAB Therapeutics AB (IRLAB-A) currently trades at kr 1.71, while our model-based Fair Value estimate is kr 0.4420, implying the stock looks roughly 286.8% overvalued today. The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector. Bull case: the Dividend Discount group reads highest at a median of kr 0.4100 per share, and 0 of the 3 models we run sit above the kr 1.71 price. Bear case: the Asset-Based group reads lowest at kr 0.2400, and 3 of the 3 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, IRLAB Therapeutics AB generated revenue of 92.5M SEK at a net margin of −72.4%. The balance sheet holds a net cash position of 51.9M SEK. Fundamentals as of Aug 22, 2026
Our scenario range runs from kr 0.2465 (bear case) to kr 0.6120 (bull case); at kr 1.71, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 77% below its 52-week high and 46% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −59% fair-value upside, at −74%, IRLAB-A screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 3 models by family
Widest divergence: Dividend Discount (kr 0.4100) versus Asset-Based (kr 0.2400). Highest evidence: Gordon GGM (64).
Notify me when IRLAB-A reaches fair value
Put IRLAB-A on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 26 · Market factors (momentum, volatility) 40
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States.
Full company description
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pirepemat (IRL752), which is in a Phase IIB clinical trial to reduce the risk of falling and falls in Parkinson's disease, and in a Phase IIA clinical trial for dementia in Parkinson's disease; and IRL757, which is in a Phase I clinical trial for the treatment of apathy in Parkinson's and other neurological disorders. It is also developing products in the preclinical stage, such as IRL942, an oral tablet for the treatment of cognitive deficits in Parkinson's and other neurological disorders; and IRL1117, an oral treatment for the hallmark symptoms of Parkinson's. In addition, the company develops P003, a research project that discovers and develops dopamine D1 and D2 receptor agonist compounds for the treatment of Parkinson's core motor symptoms. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is headquartered in Gothenburg, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
IRLAB Therapeutics AB reported revenue of 57.5M SEK in FY2025 versus 208M SEK in FY2021, a compound −27.5%/yr. Reported net income was −110M SEK in FY2025.
IRLAB-A screens 287% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 625 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | −69% |
| BioNTech SE BNTX | $111.40 | $45.66 | −59% |
| Incyte Corporation INCY | $123.22 | $115.79 | −6% |
Compare IRLAB Therapeutics AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is IRLAB Therapeutics AB (IRLAB-A) overvalued or undervalued?
What is the fair value of IRLAB-A?
What is the quality score of IRLAB-A?
What is the revenue of IRLAB Therapeutics AB (IRLAB-A)?
What is the net profit margin of IRLAB-A?
Does IRLAB Therapeutics AB pay a dividend?
Watch IRLAB Therapeutics AB in the live analysis
One click puts IRLAB Therapeutics AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.